乳腺癌肝转移肝切除术后患者预后影响因素分析

doi:10.3877/cma.j.issn.2095-3232.2020.04.008

中华肝脏外科手术学电子杂志 ›› 2020, Vol. 09 ›› Issue (04) : 329 -332. doi: 10.3877/cma.j.issn.2095-3232.2020.04.008

所属专题：文献；

临床研究

乳腺癌肝转移肝切除术后患者预后影响因素分析

徐伟熙¹, 陈钦昌², 翁子晋³, 邱万寿⁴, 黄泽楠⁴^,^†(

)

^1. 510630　广州，中山大学附属第三医院甲乳外科；523900　广东省东莞市虎门医院普通外科
^2. 510080　广州，中山大学附属第一医院普通外科
^3. 510630　广州，中山大学附属第三医院病理科
^4. 510630　广州，中山大学附属第三医院甲乳外科

收稿日期:2020-04-06 出版日期:2020-08-10
通信作者: 黄泽楠
基金资助:
国家自然青年科学基金(81502271); 广东省药学会女性肿瘤用药研究基金项目(2014D09)

Prognostic factors for patients with breast cancer liver metastases after hepatectomy

Weixi Xu¹, Qinchang Chen², Zijin Weng³, Wanshou Qiu⁴, Zenan Huang⁴^,^†()

^1. Department of Thyroid and Breast Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China; Department of General Surgery, Humen Hospital of Dongguan, Dongguan 523900, China
^2. Department of General Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
^3. Department of Pathology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
^4. Department of Thyroid and Breast Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

Received:2020-04-06 Published:2020-08-10
Corresponding author: Zenan Huang
About author:
Corresponding author: Huang Zenan, Email: sumshzn@163.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

徐伟熙, 陈钦昌, 翁子晋, 邱万寿, 黄泽楠. 乳腺癌肝转移肝切除术后患者预后影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2020, 09(04): 329-332.

Weixi Xu, Qinchang Chen, Zijin Weng, Wanshou Qiu, Zenan Huang. Prognostic factors for patients with breast cancer liver metastases after hepatectomy[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(04): 329-332.

目的

探讨乳腺癌肝转移肝切除术后患者预后的影响因素。

方法

回顾性分析2000年1月1日至2017年12月31日在中山大学附属第三医院和中山大学附属第一医院行肝切除术的51例乳腺癌肝转移患者临床资料。患者均为女性；年龄41～72岁，中位年龄59岁。患者均签署知情同意书，符合医学伦理学规定。分析乳腺癌肝转移患者临床病理特征和生存影响因素。生存预后的单因素分析采用Log-rank检验，多因素分析采用Cox比例风险模型。

结果

肝转移灶直径中位数为25（15～50）mm，病灶数量为2（1～3）个。肝转移灶局限于单叶者38例，多叶者13例；手术切缘阴性46例，阳性切缘5例；雌激素受体（ER）阳性34例，孕激素受体（PR）阳性30例。单因素分析显示，肝转移灶直径、手术切缘、肝转移肿瘤ER与患者总体生存相关（HR=1.12，1.54，1.38；P<0.05）。多因素分析结果显示，肝转移灶直径>2.5 cm和手术切缘阳性是乳腺癌肝转移切除术后总体生存的独立危险因素（HR=1.02，1.43；P<0.05）。

结论

乳腺癌肝转移病灶以多发为主，多局限于单叶，病灶较小。肝转移灶直径和手术切缘是乳腺癌肝转移肝切除术后总体生存的独立影响因素。

关键词: 乳腺肿瘤, 肿瘤转移, 肝切除术, 预后

Objective

To explore the prognostic factors for patients with breast cancer liver metastases after hepatectomy.

Methods

Clinical data of 51 patients with breast cancer liver metastases who underwent hepatectomy at the Third and the First Affiliated Hospital of Sun Yat-sen University from January 1, 2000 to December 31, 2017 were retrospectively analyzed. All the patients were female, aged 41-72 years with a median of 59 years. The informed consents of all patients were obtained and the local ethical committee approval was received. Clinicopathological features and survival prognostic factors for the patients were analyzed. Univariate factor analysis for survival prognosis was performed using Log-rank test, and multivariate factor analysis was performed using Cox proportional hazard model.

Results

The median diameter of liver metastases was 25(15-50) mm and the number was 2(1-3). Liver lesions of 38 cases localized in single lobe and lesions of 13 cases in multiple lobes. Negative surgical margin was observed in 46 cases and positive in 5 cases. Positive estrogen receptor (ER) was observed in 34 cases and positive progesterone receptor (PR) in 30 cases. Univariate analysis indicated that diameter of liver metastases, surgical margin, and ER were associated with the overall survival (HR=1.12, 1.54, 1.38; P<0.05). Multivariate analysis showed that tumor diameter >2.5 cm and positive surgical margin were the independent risk factors for the overall survival after resection of liver metastases from breast cancer (HR=1.02, 1.43; P<0.05).

Conclusions

Liver metastases from breast cancer are mainly multiple lesions, confining to single lobe with minor diameter. Diameter of liver metastases and surgical margin were the independent factors for the overall survival of patients after resection of liver metastases from breast cancer.

Key words: Breast neoplasms, Neoplasm metastasis, Hepatectomy, Prognosis

表1 乳腺癌肝转移切除术后总体生存的影响因素分析

临床病理特征	单因素分析			多因素分析
临床病理特征	HR	95%CI	P值	HR	95%CI	P值
年龄>60岁	1.08	0.91～1.17	0.27	?	?	?
乳腺癌T3～T4期	1.27	0.84～1.27	0.37	?	?	?
乳腺癌淋巴结转移	1.69	0.79～3.24	0.24	?	?	?
乳腺癌ER（-）	1.39	0.44～1.89	0.71	?	?	?
乳腺癌PR（-）	2.32	0.86～4.79	0.43	?	?	?
肝转移灶直径>25 mm	1.12	1.09～1.24	<0.001	1.02	1.01～1.09	<0.001
肝转移灶多发	1.23	0.94～1.56	0.26	?	?	?
转移灶切缘阳性	1.54	1.24～3.41	<0.001	1.43	1.13～1.69	<0.001
肝转移灶多叶分布	1.62	0.87～2.32	0.36	?	?	?
肝转移灶ER（-）	1.38	1.17～2.03	<0.001	1.35	0.42～2.14	0.329
肝转移灶PR（-）	1.32	0.79～3.14	0.22	?	?	?

表1 乳腺癌肝转移切除术后总体生存的影响因素分析

临床病理特征	单因素分析			多因素分析
临床病理特征	HR	95%CI	P值	HR	95%CI	P值
年龄>60岁	1.08	0.91～1.17	0.27	?	?	?
乳腺癌T3～T4期	1.27	0.84～1.27	0.37	?	?	?
乳腺癌淋巴结转移	1.69	0.79～3.24	0.24	?	?	?
乳腺癌ER（-）	1.39	0.44～1.89	0.71	?	?	?
乳腺癌PR（-）	2.32	0.86～4.79	0.43	?	?	?
肝转移灶直径>25 mm	1.12	1.09～1.24	<0.001	1.02	1.01～1.09	<0.001
肝转移灶多发	1.23	0.94～1.56	0.26	?	?	?
转移灶切缘阳性	1.54	1.24～3.41	<0.001	1.43	1.13～1.69	<0.001
肝转移灶多叶分布	1.62	0.87～2.32	0.36	?	?	?
肝转移灶ER（-）	1.38	1.17～2.03	<0.001	1.35	0.42～2.14	0.329
肝转移灶PR（-）	1.32	0.79～3.14	0.22	?	?	?

[1]	DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state[J]. CA Cancer J Clin, 2017, 67(6):439-448.
[2]	Singh SK, Singh S, Lillard JW Jr, et al. Drug delivery approaches for breast cancer[J]. Int J Nanomedicine, 2017(12):6205-6218.
[3]	Jemal A, Robbins AS, Lin CC, et al. Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013[J]. J Clin Oncol, 2018, 36(1): 14-24.
[4]	Spolverato G, Vitale A, Bagante F, et al. Liver resection for breast cancer liver metastases: a cost-utility analysis[J]. Ann Surg, 2017, 265(4):792-799.
[5]	Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients[J]. Breast Cancer Res Treat, 1999, 56(1):67-78.
[6]	Charalampoudis P, Mantas D, Sotiropoulos GC, et al. Surgery for liver metastases from breast cancer[J]. Future Oncol, 2015, 11(10): 1519-1530.
[7]	Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer[J]. Adv Exp Med Biol, 2007(608):1-22.
[8]	Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2015, 373(3):209-219.
[9]	Page AJ, Weiss MJ, Pawlik TM. Surgical management of noncolorectal cancer liver metastases[J]. Cancer, 2014, 120(20): 3111-3121.
[10]	Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis[J]. J Am Coll Surg, 2012, 214(5):769-777.
[11]	Elias D, Maisonnette F, Druet-Cabanac M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer[J]. Am J Surg, 2003, 185(2):158-164.
[12]	Abbas H, Erridge S, Sodergren MH, et al. Breast cancer liver metastases in a UK tertiary centre: outcomes following referral to tumour board meeting[J]. Int J Surg, 2017(44):152-159.
[13]	竺美珍，俞洋，杨红健．乳腺癌寡转移的局部治疗进展[J/CD].中华乳腺病杂志（电子版），2019, 13(3):182-186.
[14]	Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer?[J]. Ann Surg, 2006, 244(6):897-907.
[15]	Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases[J]. Ann Surg Oncol, 2004, 11(9):869-874.
[16]	Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) dagger[J]. Ann Oncol, 2018, 29(8):1634-1657.
[17]	中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范（2017年版）[J]．中国癌症杂志，2017, 27(9):695-759.
[18]	王俊男，徐拯，林健，等．乳腺癌肝转移患者的临床病理特征及预后因素分析：基于SEER数据库的回顾性研究[J/CD]．中华乳腺病杂志（电子版），2018, 12(4):202-208.
[19]	Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome[J]. Surgery, 2012, 151(5):710-716.
[20]	van Walsum GA, de Ridder JA, Verhoef C, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors[J]. Eur J Surg Oncol, 2012, 38(10): 910-917.

[1]	李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6]	冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[7]	韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[8]	陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9]	关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10]	焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[11]	张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12]	陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13]	吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[14]	吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[15]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic factors for patients with breast cancer liver metastases after hepatectomy

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic factors for patients with breast cancer liver metastases after hepatectomy